Printer Friendly

DEPRENYL RESEARCH COMMENTS ON NEWSPAPER REPORT

 DEPRENYL RESEARCH COMMENTS ON NEWSPAPER REPORT
 TORONTO, Jan. 10 /PRNewswire/ -- Deprenyl Research Limited's


(NASDAQ: DEPLF) audited 1991 earnings will not be available until later this month, the company said today. A report in today's Financial Post suggests that there will be an "earnings dip" for the 1991 financial year. In actual fact, preliminary figures indicate that 1991 was a record year with increases in sales, revenue, total earnings and earnings per share over 1990 levels.
 Deprenyl Research Limited is an independent Canadian pharmaceutical company which markets drugs to treat central nervous system disorders. Its principal product is Eldepryl(R) which is used to treat Parkinson's disease.
 -0- 1/10/92
 /CONTACT: Morton P. Shulman, M.D., co-chairman, or James P. Doherty, president, both of Deprenyl Research, 416-537-4372, or fax, 416-537-1653; or Irving L. Straus of Straus Corporate Communications, 212-768-2477, or fax, 212-768-2476, for Deprenyl Research/
 (DEPLF) CO: Deprenyl Research Limited ST: Ontario IN: MTC SU:


CK-KW -- NY029 -- 8589 01/10/92 11:20 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 10, 1992
Words:164
Previous Article:AT&T AND THE FLORIDA HOTEL & MOTEL ASSOCIATION ANNOUNCE AGREEMENT
Next Article:ILLINOIS POWER $1.6 BILLION 'BBB-' DEBT ON FITCHALERT POSITIVE -- FITCH FINANCIAL WIRE --
Topics:


Related Articles
CANGUARD HEALTH TECHNOLOGIES INC. RESPONDS TO COMMENTS ON DEPRENYL RESEARCH LTD. PRESS RELEASE
CANGUARD HEALTH TECHNOLOGIES INC. RESPONDS TO LAWSUIT ANNOUNCED IN PRESS ON DEC. 3
DEPRENYL ADJOURNS APPLICATION FOR INJUNCTION
CANGUARD HEALTH TECHNOLOGIES RESPONSE TO DEPRENYL RELEASE
DEPRENYL RESEARCH LIMITED REPORTS EARNINGS
DEPRENYL RESEARCH COMMENTS ON STOCK PRICE
DEPRENYL RESEARCH CHAIRMAN ISSUES STATEMENT ON SELL ADVISORY
DEPRENYL RESEARCH SETS THE FACTS STRAIGHT
DEPRENYL RESEARCH SETS THE FACTS STRAIGHT
DEPRENYL RESEARCH REPORTS EARNINGS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters